RCC treatment has developed significantly, as vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors and drugs that inhibit mammalian target of rapamycin (mTOR) signaling have become the mainstay for the management of advanced RCC. This evidence concerns the gene MTOR and renal cell carcinoma.